iBio, Inc. business relationships
Companies named in iBio, Inc.’s 10-K filed 2026-08-28, and public companies whose annual reports name iBio, Inc.. Each link shows the sentence it came from. Scores are Engagemii’s AI visibility scores.
- AEO visibility
- 5.2 / 10
- AI naming
- 38 / 100 Top 1% in its category
- Agent readiness
- 0 / 100
- AI adoption
- 8 / 100
Layers: GLP-1 & obesity
Named in iBio, Inc.’s annual report 2
“...August 27, 2026, we entered into an exclusive license agreement related to Amylin (the "Amylin License Agreement") with AstralBio, Inc. ("AstralBio"), pursuant to which AstralBio has licensed to us, on a worldwide exclusive basis and with the right to grant sublicenses, under the AstralBio Licensed...” SEC filing
“In April 2024, as result of the collaboration with AstralBio, Inc. ("AstralBio") we initiated a program to discover and develop a long-acting anti-myostatin antibody.” SEC filing
Links are read automatically from SEC annual reports (10-K, 20-F, 40-F). In a hand check of random links, about 8 in 10 were real business relationships, so every link carries its source sentence.